‘Korean bio ventures gradual in catching needs of medical neighborhood, trade’

Thank you for reading this post, don't forget to subscribe!

Philip Tagari, vice chair for Amgen’s R&D, speaks during a recent interview with Korea Biomedical Review.
Philip Tagari, vice chair for Amgen’s R&D, speaks throughout a current interview with Korea Biomedical Evaluation.


“Korean biotechnology corporations’ scientific high quality doesn’t lag behind different nations. Nonetheless, they fall considerably wanting understanding what the medical neighborhood and biotech trade need.”


So stated Philip Tagari, vice chair for Amgen’s R&D, who visited Korea to attend the “Second KHIDI-AMGEN Science Academy: Bio Day” whereas commenting on the Korean biotech corporations.


Korea has performed “KHIDI-AMGEN Science Academy: Pitching Day” or “Bio Day” occasions to search out Korean biotech corporations able to growing modern expertise and cooperating with the Korea Well being Trade Growth Institute (KHIDI).


Amgen is a world pharma firm recognized particularly for brisk R&D and open innovation actions. Vice Chairman Tagari is in control of analysis and growth on the firm.


Korea Biomedical Evaluation met with Tagari to listen to concerning the potential of Korean biotech corporations as open innovation companions and Amgen’s R&D plans.


Query: What’s the aim of your go to?


Reply: I’m visiting Korea to attend the “Bio Day” occasion. The occasion is a crucial alternative to introduce Amgen’s ongoing analysis in fundamental science to Korean scientific and medical communities and meet modern Korean bio ventures to hunt open innovation and heighten entry to one another by way of networking. I additionally met three Korean corporations chosen in the course of the “Pitching Day” even in September and supported their biotechnological innovation.


Q: Do you may have standards for choosing companions as Amgen’s highest R&D official?


A: In looking for potential collaboration companions and funding alternatives, I pay the best consideration to their “High quality of Science.” As you recognize, Amgen is an organization primarily based on life science, and due to this fact, it locations “Biology First” on the heart of its technique in approaching the R&D of latest medication. Based mostly on these standards, we consider and analyze how stable a possible associate’s scientific foundation is with a significantly strict normal.


we watch how nicely the potential companions match with Amgen’s flagship remedy areas, equivalent to oncology, cardiovascular illnesses, and inflammatory illnesses, or different areas during which we might have pursuits at some particular time. We additionally observe their expertise or researchers and the way a lot and in what methods they’ve developed over the previous few years. Lastly, we watch their managerial soundness {and professional} enthusiasm.


Q: You chose Korean bio ventures in the course of the “Pitching Day” occasion in September. How did you are feeling about Korean startups’ ranges and capabilities?


A: We maintain related occasions worldwide, starting from Los Angeles and San Francisco to Vancouver, British Columbia, Cambridge, Massachusetts, Taiwan, and Singapore. In conclusion, the standard of science of Korean corporations we met in the course of the Pitching Day occasion was similar to these of overseas corporations in these cities and nations.


these startups confirmed a slight lack of expertise of what the medical neighborhood and biotechnology trade wanted of them. This appears to be as a result of Korean bio ventures have had comparatively fewer exposures to and exchanges with the medical neighborhood or overseas biopharma corporations. Due to this fact, I’ll advise Korea’s promising biopharma corporations will make brisk exchanges with their world counterparts on the event of occasions, equivalent to “Bio Day” and “Pitching Day,’ and search to be taught concerning the “wants” and “pursuits” of the medical neighborhood,” and the “stage of expectations” on these corporations’ innovation.


Whereas performing the occasion, I additionally offered preliminary mentoring to corporations on the record of the main-round competitors and located variations from overseas corporations on this side. For instance, Korean enterprise officers confirmed appreciable formalities and appeared extra in enterprise than science. So, I coached them to attend the occasion with knowledge specializing in contents wanted by the medical neighborhood and the trade, along with the high-quality expertise that they had. Overseas corporations suppose these components are necessary in looking for overseas companions.


Q: Have been there any memorable corporations whereas conducting the Pitching Day occasion? If that’s the case, why?


A: An organization launched an attention-grabbing expertise. Basgen Bio, which analyzes state-of-the-art genetic knowledge and Korea’s digital medical file (EMR) knowledge, demonstrated appreciable scientific high quality and evaluation abilities to turn into one of many winners in the course of the Pitching Day occasion.


Whereas assembly with the corporate, I recalled Dr. Kari Stefansson, head of Amgen’s genetics analysis and one of many world’s prime authorities on this space. Dr. Kari based Amgen’s subsidiary, deCODE Genetics, which conducts research that detect and determine the targets of illnesses primarily based on genetics. By means of this occasion, I felt that Korean bio ventures’ expertise may compete with overseas corporations associated to human genetics shoulder to shoulder.

Supply hyperlink